Nabriva journal publications - Lefamulin (BC-3781)

Waites KB, Crabb DM, Duffy LB, Jensen JS, Liu Y, Paukner S.
In Vitro Activity of Lefamulin and Other Antimicrobial Agents Against Macrolide-Susceptible and Macrolide-Resistant Mycoplasma pneumoniae from the United States, Europe, and China
Antimicrob Agents Chemother. 2016 Nov 14. pii: AAC.02008-16. [Epub ahead of print]

Mendes RE, Farrell DJ, Flamm RK, Talbot GH, Ivezic-Schoenfeld Z, Paukner S, Sader HS.
In Vitro Activity of Lefamulin Tested against Streptococcus pneumoniae with Defined Serotypes, Including Multidrug-Resistant Isolates Causing Lower Respiratory Tract Infections in the United States.
Antimicrob Agents Chemother. 2016 Jun 20;60(7):4407-11.

M. Zeitlinger, R. Schwameis, A. Burian1, B. Burian1, P. Matzneller1, M. Müller, W. W. Wicha, D. B. Strickmann and W. Prince
Simultaneous assessment of the pharmacokinetics of a pleuromutilin, lefamulin, in plasma, soft tissues and pulmonary epithelial lining fluid
Antimicrob. Chemother. (2016) 71 (4): 1022-1026. doi: 10.1093/jac/dkv442 First published online: January 7, 2016

Zohar Eyala; Donna Matzova; Miri Krupkina; Itai Wekselmana; Susanne Pauknerb; Ella Zimmermana; Haim Rozenberga; Anat Bashana; Ada Yonath
Structural insights into species-specific features of the ribosome from the pathogen Staphylococcus aureus
Proc Natl Acad Sci U S A. 2015 Oct 27; 112(43): E5805–E5814.  Published online 2015 Oct 13. doi:  10.1073/pnas.1517952112

Paukner, S.; Sader, H.S.; Ivezic-Schoenfeld, Z.; Jones, R.N.
Antimicrobial activity of the pleuromutilin antibiotic BC-3781 against bacterial pathogens isolated in the SENTRY antimicrobial surveillance program (2010)
Antimicrob. Agents Chemother. 57(9) (2013) 4489-4495

Prince, W.T.; Ivezic-Schoenfeld, Z.; Lell, C.; Tack, K. J.; Novak, R.; Obermayr, F.; Talbot, G.H.
Phase II clinical study of BC-3781, a pleuromutilin antibiotic, in treatment of patients with acute bacterial skin and skin structure infections
Antimicrob. Agents Chemother. 57(3) (2012) 2087-2094

Sader, H.S.; Paukner, S.; Ivezic-Schoenfeld, Z.; Biedenbach, D.J.; Schmitz, F‑J.; Jones, R.N. 
Antimicrobial activity of the novel pleuromutilin antibiotic BC‑3781 against organisms responsible for community-acquired respiratory tract infections (CARTIs)
J. Antimicrob. Chemother. 67(5) (2012) 1170-1175

Sader, H.S.; Biedenbach, D.J.; Paukner, S.; Ivezic-Schoenfeld, Z.; Jones, R.N.
Antimicrobial activity of the investigational pleuromutilin compound BC-3781 tested against Gram-positive organisms commonly cssociated with acute bacterial skin and skin structure Infections
Antimicrob. Agents Chemother. 56(3) (2012) 1619-1623

Ross, J.E.; Sader, H.S.; Ivezic-Schoenfeld, Z.; Paukner, S.; Jones, R.N.
Disk diffusion and MIC quality control ranges for BC-3205 and BC‑3781, two novel pleuromutilin antibiotics
J. Clin. Microbiol. 50(10) (2012) 3361-3364

Novak, R.
Are pleuromutilin antibiotics finally fit for human use
Ann. N.Y. Acad. Sci. 1241 (2011) 71–81

Novak, R. and Shlaes, D.M.
The pleuromutilin antibiotics: A new class for human use
Curr. Opin. Inv. Drugs 11(2) (2010) 182-191